M&A and investment decisions across Life Sciences and Healthcare involve significant uncertainty and high stakes. Whether acquiring products, platforms, service providers, or care delivery assets, investors and corporate buyers must assess the true commercial potential, scalability, and risks of a target before committing capital. Without robust commercial due diligence, buyers risk overestimating growth, underestimating execution complexity, or missing structural weaknesses in markets, business models, or customer dynamics.
We support investors and strategic buyers with end-to-end commercial due diligence across a broad range of Life Sciences and Healthcare verticals, including pharmaceuticals, MedTech, diagnostics, Consumer Health, pharma services (CROs, CDMOs, testing platforms), and healthcare services (pharmacy networks, care centers, patient services). Our work combines outside-in market analysis, competitive intelligence, customer and stakeholder interviews, pricing and reimbursement assessment, and demand modeling to build an objective view of market attractiveness and competitive positioning.We conduct different types of due diligence depending on deal context, including red-flag reviews, Phase 1 and Phase 2 commercial DD, and deep outside-in assessments to stress-test management assumptions. Beyond market sizing and forecasts, we assess go-to-market models, customer concentration, scalability, regulatory exposure, and execution risks. Our outputs highlight upside potential, key sensitivities, and downside risks, enabling clients to make informed investment decisions, refine valuation assumptions, and identify early value-creation levers.
